GSK
Price
$39.53
Change
+$0.09 (+0.23%)
Updated
Aug 29, 04:01 PM (EDT)
Capitalization
80.35B
61 days until earnings call
JNJ
Price
$177.32
Change
+$1.87 (+1.07%)
Updated
Aug 29, 04:06 PM (EDT)
Capitalization
422.54B
53 days until earnings call
Interact to see
Advertisement

GSK vs JNJ

Header iconGSK vs JNJ Comparison
Open Charts GSK vs JNJBanner chart's image
GSK
Price$39.53
Change+$0.09 (+0.23%)
Volume$2.31K
Capitalization80.35B
Johnson & Johnson
Price$177.32
Change+$1.87 (+1.07%)
Volume$3.11K
Capitalization422.54B
GSK vs JNJ Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. JNJ commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (GSK: $39.44 vs. JNJ: $175.45)
Brand notoriety: GSK: Not notable vs. JNJ: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 99% vs. JNJ: 74%
Market capitalization -- GSK: $80.35B vs. JNJ: $422.54B
GSK [@Pharmaceuticals: Major] is valued at $80.35B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $422.54B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s).

  • GSK’s FA Score: 1 green, 4 red.
  • JNJ’s FA Score: 3 green, 2 red.
According to our system of comparison, JNJ is a better buy in the long-term than GSK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 6 TA indicator(s) are bullish while JNJ’s TA Score has 2 bullish TA indicator(s).

  • GSK’s TA Score: 6 bullish, 4 bearish.
  • JNJ’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than JNJ.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -1.60% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

JNJ is expected to report earnings on Oct 21, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($423B) has a higher market cap than GSK($80.3B). JNJ has higher P/E ratio than GSK: JNJ (18.78) vs GSK (17.69). JNJ YTD gains are higher at: 24.243 vs. GSK (20.573). JNJ has higher annual earnings (EBITDA): 35.6B vs. GSK (8.61B). GSK has more cash in the bank: 3.62B vs. JNJ (3.25B). GSK has less debt than JNJ: GSK (17.4B) vs JNJ (50.8B). JNJ has higher revenues than GSK: JNJ (90.6B) vs GSK (31.6B).
GSKJNJGSK / JNJ
Capitalization80.3B423B19%
EBITDA8.61B35.6B24%
Gain YTD20.57324.24385%
P/E Ratio17.6918.7894%
Revenue31.6B90.6B35%
Total Cash3.62B3.25B111%
Total Debt17.4B50.8B34%
FUNDAMENTALS RATINGS
GSK vs JNJ: Fundamental Ratings
GSK
JNJ
OUTLOOK RATING
1..100
2318
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
6829
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5323
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (7) in the Pharmaceuticals Major industry is in the same range as JNJ (16). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.

JNJ's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (68). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.

JNJ's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as GSK (100). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

JNJ's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as GSK (53). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

JNJ's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as GSK (100). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKJNJ
RSI
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
36%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 8 days ago
41%
Declines
ODDS (%)
Bearish Trend 24 days ago
54%
Bearish Trend 4 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
48%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MEM33.720.36
+1.09%
Matthews Emerging Markets Eq Actv ETF
AVES55.900.32
+0.57%
Avantis Emerging Markets Value ETF
IUSG158.830.82
+0.52%
iShares Core S&P US Growth ETF
DUKQ27.020.06
+0.24%
Ocean Park Domestic ETF
MFUS54.96-0.03
-0.05%
PIMCO RAFI Dyn Multi-Factor US Eq ETF

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-1.18%
NVS - GSK
67%
Closely correlated
-0.33%
AZN - GSK
63%
Loosely correlated
+0.08%
PFE - GSK
57%
Loosely correlated
-1.87%
SNY - GSK
55%
Loosely correlated
-0.34%
JNJ - GSK
49%
Loosely correlated
-0.76%
More

JNJ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JNJ
1D Price
Change %
JNJ100%
-0.76%
PFE - JNJ
59%
Loosely correlated
-1.87%
NVS - JNJ
54%
Loosely correlated
-0.33%
GSK - JNJ
49%
Loosely correlated
-1.18%
BIIB - JNJ
44%
Loosely correlated
-2.72%
SNY - JNJ
43%
Loosely correlated
-0.34%
More